Skip to main content

Ryoncil FDA Approval History

FDA Approved: Yes (First approved December 18, 2024)
Brand name: Ryoncil
Generic name: remestemcel-L-rknd
Dosage form: Cell Suspension for Intravenous Infusion
Company: Mesoblast Limited
Treatment for: Graft Versus Host Disease

Ryoncil (remestemcel-L-rknd) is an allogeneic bone marrow-derived mesenchymal stromal cell therapy indicated for the treatment of steroid-refractory acute graft versus host disease in pediatric patients 2 months of age and older.

Development timeline for Ryoncil

DateArticle
Dec 18, 2024Approval FDA Approves Ryoncil (remestemcel-L-rknd) Mesenchymal Stromal Cell Therapy for Steroid-Refractory Acute Graft Versus Host Disease
Jul  6, 2020Expanded Access Protocol Initiated for Compassionate Use of Remestemcel-L in Children With Multisystem Inflammatory Syndrome Associated With COVID-19
Apr  6, 2020FDA Clears IND for Remestemcel Use in COVID-19 ARDS Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Medical Disclaimer